Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

40.60 +1.52 (+3.90%)
Delayed Quote Updated: 12:57 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter... 
Via StockStory
Topics Bonds Government
News headline image
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r... 
Via StockStory
Topics Bonds Economy
News headline image
Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NY... 
Via StockStory
News headline image
2 Volatile Stocks with Promising Prospects and 1 We Ignore
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be... 
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input... 
Via StockStory
News headline image
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Economy
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta... 
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and... 
Via StockStory
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group
Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft... 
Via StockStory
Topics Artificial Intelligence Credit Cards
News headline image
Why Azenta (AZTA) Stock Is Down Today
What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, t... 
Via StockStory
News headline image
1 Momentum Stock for Long-Term Investors and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
Azenta (AZTA) Q3 2026 Earnings Call Transcript ↗
Recurring revenue tops 50% as automation investments drive operational progress. 
Via The Motley Fool
Topics Earnings
News headline image
The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call
Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this ... 
Via StockStory
Topics Earnings
News headline image
Azenta Q3 Earnings Call Highlights ↗
Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued... 
Via MarketBeat
Topics Earnings
News headline image
Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026
Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAA... 
Via StockStory
News headline image
Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday after the bell. Here’s what investors should know. Azenta missed analysts’ ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Cash-Burning Stocks Walking a Fine Line
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Cabot Corporation Announces Planned Leadership Transition
Company Announces Retirement of President and CEO Sean Keohane and Appointment of Erica McLaughlin as Successor 
From Cabot Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.